The use of oxygen therapy (high doses of oxygen - hyperoxia) in the treatment of premature infants results in their survival. However, it also results in a high incidence of chronic lung disease known as bronchopulmonary dysplasia, a disease in which airway hyper-responsiveness and pulmonary hypertension are well known as consequences. In our previous studies, we have shown that hyperoxia causes airway hyper-reactivity, characterized by an increased constrictive and impaired airway smooth muscle relaxation due to a reduced release of relaxant molecules such as nitric oxide, measured under in vivo and in vitro conditions (extra- and intrapulmonary) airways. In addition, the relaxation pathway of the vasoactive intestinal peptide (VIP) and/or pituitary adenylate cyclase activating peptide (PACAP) is another part of this system that plays an important role in the airway caliber. Peptide, which activates VIP cyclase and pituitary adenylate cyclase, has prolonged airway smooth muscle activity. It has long been known that VIP inhibits airway smooth muscle cell proliferation in a mouse model of asthma, but there is no data about its role in the regulation of airway and tracheal smooth muscle contractility during hyperoxic exposure of preterm newborns.
- MeSH
- bronchopulmonální dysplazie etiologie metabolismus patofyziologie MeSH
- gestační stáří MeSH
- hladké svalstvo metabolismus patofyziologie MeSH
- hyperoxie etiologie metabolismus patofyziologie MeSH
- hypofyzární adenylátcyklázu aktivující peptid metabolismus MeSH
- lidé MeSH
- modely nemocí na zvířatech MeSH
- novorozená zvířata MeSH
- novorozenec nedonošený * MeSH
- novorozenec MeSH
- oxygenoterapie škodlivé účinky MeSH
- plíce metabolismus patofyziologie MeSH
- předčasný porod * MeSH
- remodelace dýchacích cest MeSH
- signální transdukce MeSH
- vazoaktivní intestinální peptid metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- novorozenec MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
